Substantial savings opportunities exist by using lower-cost biologics for patients with plaque psoriasis, according to one ...

Clinical efficacy was evaluated using the Psoriasis Area and Severity Index (PASI), along with metabolic indicators such as ...

A new study in Scientific Reports reveals that skin shame is a key psychological burden for people with atopic dermatitis and ...

Art Garfunkel discusses his experience living with psoriasis as part of Sun Pharma’s I LUV YA for The Long Haul campaign.

THOUGHT you’d nailed your beauty regime? Even if you’re using all the right products, you might still be damaging your health ...

Icotrokinra appears to be an effective treatment for adolescents with moderate to severe plaque psoriasis, according to a subgroup analysis of the ICONIC-LEAD study.

In this video, Raj Chovatiya, MD, PhD, discusses findings from the phase 2 STRIDE trial presented at this year’s American ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

Q1 2025 Earnings Call Transcript April 15, 2025 Johnson & Johnson beats earnings expectations. Reported EPS is $2.77, expectations were $2.58. Operator: Good morning, and welcome to Johnson & ...

Results from a subgroup of the ICONIC-LEAD study show 75% of adolescents with plaque psoriasis achieved completely clear skin ...

Icotrokinra is efficacious and safe for treating moderate to severe plaque psoriasis among adolescents and adults when compared with placebo.

The psoriasis pipeline possesses some drugs in mid- and late-stage development to be approved in the near future. The emerging landscape holds a diverse range of therapeutic alternatives for treatment ...